期刊文献+

他汀类药物抗骨质疏松治疗的研究进展 被引量:3

原文传递
导出
摘要 随着我国人口老龄化加速,中国50岁以上老年人在2020年预计增至4.69亿,2050年我国预计增至5.71亿,而2006年的一项调查估算我国50岁以上约有6 944万人患骨质疏松症,约21 390万人存在低骨量。据估算,2006年用于骨质疏松症导致的髋部骨折治疗的医疗高达达103.8亿元,预计2020年会增至850亿元以上,2050年则将达18 000亿元[1]。
作者 钱文彬 陈扬
出处 《中国骨与关节损伤杂志》 2015年第3期334-335,共2页 Chinese Journal of Bone and Joint Injury
基金 广东省建设中医药强省科研课题(20141257)
  • 相关文献

参考文献21

  • 1中国健康促进基金会骨质疏松防治中国白皮书编委会.骨质疏松症中国白皮书.中华健康管理学杂志,2009,3(3):148-156.
  • 2万瑞融,黄振光,丘岳,王希斌.他汀类药物多效性的研究进展[J].内科,2013,8(3):300-301. 被引量:10
  • 3赵心彬,倪敏,陶霞.他汀类药物多效药理作用及其机制研究进展[J].药学实践杂志,2013,31(1):19-21. 被引量:22
  • 4Gotoh M, Mizuno K,Ono Y,et al. Fluvnstatin increases bone mineral density in postmenopausal women [J]. Fuknshima J Med Sci, 2011,57(1): 19-27.
  • 5谢莲娜,钟雪焱,王丽君,孙玉兰,王中华,秦颖,刘新荣.阿托伐他汀对老年冠心病患者骨密度的影响[J].临床心血管病杂志,2008,24(2):103-105. 被引量:8
  • 6Mundy G,Garrett R,Harris S ,et al Stimulation of bone formation in vitro and in rodents by statins[j]. Science, 1999,286(5446): 1946-1949.
  • 7Sugiyama M,Kodama T,Konishi K,et al. Compaction and simvas- tatin,but not pravastatin ,include bone morpbogenetic protein-2 in human osteosareoma cells [j]. Biechem Biophys Res Commun, 2000,271 (3) : 688-692.
  • 8Park JB. Combination of simvastatin and bone morpbogenetic pro- tein-2 enhances the differentiation of osteoldasts by regulating the expression of phospho-Smadl/5/8 [J]. Experimental and therapeutic medicine, 2012,4(2) : 303-306.
  • 9Song C ,Wang J,Song Q ,et al. Simvastatin induces estrogen recep- tor-alpha(ER-alpha) in routine bone marrow stromal cells[J]. J Bone Miner Metal>,2008,26(3) :213-217.
  • 10Abdul-Majecd S,Mohamed N,soelaiman IN. Effects of tocotrienol and lovastatin combination on osteoldast and estooclast activity in estrogen-deficient osteoporosis [J]. Evid-Based Complement Alter- nat Med ,2012,2012: 960742.

二级参考文献67

共引文献127

同被引文献54

  • 1杨开燕,钟栩.中医药诊治血脂异常[J].中国老年学杂志,2015,35(1):251-253. 被引量:9
  • 2周学文,陈民,李曦明,白光,周奇,姜树民.血脂异常中医病因病机探讨[J].中华中医药学刊,2007,25(2):197-198. 被引量:32
  • 3Liu Z,Weaver J,De Papp A,et al.Disparities in osteoporosis treat- ments[J].Osteoporos Int,2016,27(2):509-519.
  • 4Marques AfFerreira RJ,Santos E,et al.The accuracy of osteoporotic fracture risk prediction tools:a systematic review and meta-analysis [J].Ann Rheum Dis,2015,74(11):1958-1967.
  • 5Nguyen TV,Seeman E.Osteoporosis:treat and live,or let die twice more likely[J].J Bone Miner Res,2015,30(9):1551-1552.
  • 6Morabito N,Catalano A,Gaudio A,et al.Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major -related osteoporosis[J].J Bone Miner Metab,2015,PMID:26204844.
  • 7Leslie WD,Brennan -Olsen SL,Morin SN,et al.Fracture prediction from repeat BMD measurements in clinical practice[J],Osteoporos Int,2016,27(1):203-210.
  • 8Schmidt J,Dahlgren E,Brannstrom M,et al.Body composition,bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome-a long-term follow-up study[J].Clin En- docrinol(Oxf),2012,77(2):207-214.
  • 9Albertazzi P,Bottazzi M,Steel SA.Bone mineral density and depot medroxyprogesterone acetate[J].Contraception,2006,73(6):577-583.
  • 10Watson SL,Weeks BK,Weis LJ,et al.Heavy resistance training is safe and improves bone,function,and stature in postmenopausal women with low to very low bone mass:novel early findings from the LIFTMOR trial[J].Osteoporos Int,2015,26(12):2889-2894.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部